Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 12, Issue 10, 2012, Pages 781-789

  Malagón, Talía ^a,b   Drolet, Mélanie ^a,b   Boily, Marie Claude ^a,c   Franco, Eduardo L ^d   Jit, Mark ^e,f   Brisson, Jacques ^a,b   Brisson, Marc ^a,b  

^a Fonds de la Recherche en Sante du Quebec   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HPV 007; HPV 023; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ARTICLE; COMPARATIVE EFFECTIVENESS; CROSS PROTECTION; DATA BASE; DATA EXTRACTION; DRUG EFFICACY; FOLLOW UP; GENETIC HETEROGENEITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; META ANALYSIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

CHI-SQUARE DISTRIBUTION; CROSS PROTECTION; HUMAN PAPILLOMAVIRUS 31; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84866628242     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70187-1     Document Type: Article

References (43)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
2. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-1636.
3. Backes DM, Kurman RJ, Pimenta JM, Smith JS Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009, 20:449-457.
4. Kreimer AR, Clifford GM, Boyle P, Franceschi S Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14:467-475.
5. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056. on behalf of the Retrospective International Survey and HPV Time Trends Study Group.
6. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
7. Brisson M, Van de Velde N, De Wals P, Boily MC The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007, 25:5399-5408.
8. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314. for the HPV PATRICIA Study Group.
9. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255. on behalf of the HPV Vaccine Study group.
10. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009, 199:936-944.
11. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
12. Jit M, Chapman R, Hughes O, Choi YH Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775.
13. Capri S, Gasparini R, Panatto D, Demarteau N Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross protection profiles. Gynecol Oncol 2011, 121:514-521.
14. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
15. Merck vaccines 2012 Merck Canada, (accessed Jan 27, 2012). http://www.merckfrosst.ca/merck-products/ca_en/merck-vaccines/home.html.
16. GSK: result summaries: compounds 2012 GlaxoSmithKline, (accessed Jan 27, 2012). http://www.gsk-clinicalstudyregister.com/result_compounds.jsp.
17. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H Classification of papillomaviruses. Virology 2004, 324:17-27.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
19. DerSimonian R, Laird N Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
20. Cochrane handbook for systematic reviews of interventions version 5.1.0 2011, The Cochrane Collaboration. J.P.T. Higgins, S. Green (Eds.).
21. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110. for the HPV PATRICIA Study Group.
22. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years. Lancet 2009, 374:1975-1985. The GlaxoSmithKline Vaccine HPV-007 Study Group.
23. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7·3 years in young adult women. Vaccine 2010, 28:6247-6255.
24. Malagon T, Drolet M, Boily MC, Brisson M. Issues in comparing and interpreting clinical trial measures of cross-protection. 27th International Papillomavirus Conference and Clinical Workshop (IPV); Berlin, Germany; Sept 17-22, 2011.
25. Romanowski B. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types: end-of-study results. 26th Annual International Papillomavirus Conference and Clinical Workshop (IPV); Montreal, Quebec, Canada; July 3-8, 2010.
26. Naud P. Cross-protective efficacy of the AS04-adjuvanted HPV-16/18 vaccine against oncogenic HPV-31, -33, and -45. EUROGIN 2010; Monte Carlo, Monaco; Feb 17-20, 2010.
27. Schwarz TF. The clinical impact of cross protection with the bivalent vaccine. EUROGIN 2011; Lisbon, Portugal; May 8-11, 2011.
28. Result summary for 580299/007 GlaxoSmithKline Biologicals, (accessed Jan 27, 2012). http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=580299%2f007&studyId=E6424374-9DB0-4E35-B172-EE13326E454E&compound=Human+Papillomavirus+Types+16+and+18+Vaccine.
29. Result summary for 109616 (Y7) GlaxoSmithKline Biologicals, (accessed Jan 27, 2012). http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=109616+%28Y7%29&studyId=A66CF565-EE28-4617-B03D-E49F2145BF26&compound=Human+Papillomavirus+Types+16+and+18+Vaccine.
30. Mariani L, Venuti A HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med 2010, 8:105.
31. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011, 7:1359-1373.
32. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011, 7:1343-1358.
33. Romanowski B Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin 2011, 7:161-169.
34. Draper E, Bissett SL, Howell-Jones R, et al. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 2011, 29:8585-8590.
35. Kemp TJ, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011, 29:2011-2014.
36. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168:123-137.
37. Jenkins D A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008, 110(suppl 3):S18-S25.
38. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97:1072-1079.
39. Kjaer SK, Frederiksen K, Munk C, Iftner T Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102:1478-1488.
40. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006, 44:3292-3298.
41. Kim JJ, Goldie SJ Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359:821-832.
42. Van de Velde N, Brisson M, Boily MC Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007, 165:762-775.
43. Jit M, Choi YH, Edmunds WJ Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.